Cooling to Alleviate Migraine #3
Part of paid clinical trials in Indian Harbour Beach, Florida.
- Sponsor
- Mi-Helper, Inc.
- Study ID
- NCT06874361
- Status
- Completed
Conditions
- Migraine
- Migraine Headache
- Migraine With or Without Aura
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Mi-Helper — DEVICEThe Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
Study Details
This is a prospective, double-blind, sham-controlled, randomized, decentralized trial. This study aims to assess the safety and efficacy of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home setting. Adults aged 18 years to 70 years old with a diagnosis of migraine (with or without aura) for at least one year will be recruited for this study.
Key Dates
- Start date
- Mar 24, 2025
- Status verified
- Jan 2026
- Primary completion
- Oct 29, 2025
- Completion
- Dec 15, 2025
Study Design
- Enrollment
- 156 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group I (active treatment)10 liters per minute of dehumidified air administered via Mi-Helper for 15 minutes
- Sham Comparator: Group II (sham)2 LPM of ambient air administered intermittently via Mi-Helper for 15 minutes
Primary Outcome Measure
Pain Freedom at 2 Hours Post Treatment [ Time Frame: 2 hours ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| SPRIM Pro | Indian Harbour Beach | Florida | 32937 | - |
Find similar trials in Indian Harbour Beach, FL
By condition
By specialty
By research site
Related Studies
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)PHASE3 · Recruiting · AbbVie · Huntsville, Alabama
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)PHASE3 · Enrolling By Invitation · AbbVie · Huntsville, Alabama
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsPHASE3 · Recruiting · Pfizer · Fort Smith, Arkansas
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigrainePHASE3 · Recruiting · H. Lundbeck A/S · New Haven, Connecticut